Adaptive 10-Q: Q3 Revenue $83.9M, Net Income $2.9M, Cash $400.2M
ADPT has more than doubled off its 52-week low of $12.
Summary
Adaptive's Q3 10-Q shows MRD revenue up 28% to $72.6 million, a $2.9 million quarterly profit, and $400.2 million in cash and securities after the June convertible notes deal, while Immune Medicine revenue fell 70% as Genentech revenue ended.
Key Events · Earnings and Guidance · ADPT
-
Q3 Revenue $83.9M, Small Quarterly Profit
Total revenue of $83.9 million produced net income attributable to Adaptive of $2.9 million, or $0.02 per share, versus $9.5 million in Q3 2025.
-
MRD Growth Offsets Immune Medicine Decline
MRD revenue rose 28% to $72.6 million on 39,587 clonoSEQ tests (up 46%), while Immune Medicine revenue fell 70% to $11.3 million after the Genentech collaboration ended.
-
Cash $400.2M After Convertible Notes
Cash, cash equivalents and marketable securities were $400.2 million at September 30, 2026 versus $240.2 million at year-end, following the $345.0 million 0% convertible notes issued June 22, 2026 and the $156.9 million OrbiMed royalty buyout.
-
Operating Cash Burn Narrows Sharply
Nine-month net cash used in operating activities was $6.3 million versus $48.0 million a year earlier, helped by higher customer collections; management says existing cash funds operations for at least the next 12 months.
Analysis · ADPT · Life Sciences
The headline revenue number was already out via Reuters and a concurrent 8-K, but the full 10-Q is where the balance sheet and cash story lives. MRD revenue grew 28% to $72.6 million on 46% higher clonoSEQ test volume, and the company swung to a small $2.9 million quarterly profit. More important for the thesis: cash and marketable securities stand at $400.2 million after the June convertible notes offering and the $156.9 million OrbiMed royalty buyout, and nine-month operating cash burn narrowed to $6.3 million from $48.0 million a year ago. Against that, Immune Medicine revenue fell 70% to $11.3 million as Genentech collaboration revenue disappeared, and the segment posted a $13.4 million nine-month Adjusted EBITDA loss while the separation review continues. The filing also discloses new 10b5-1 plans for the CEO and five other insiders, and a new data-hosting agreement with Harlan Robins' Harell Data Corp. — a related-party arrangement worth noting alongside the ongoing Immune Medicine separation.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADPT was trading at $28.48 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $4.3B. The 52-week trading range was $12.00 to $30.74. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.